1. Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective. (2nd December 2019) Authors: Gerbasi, Margaret E.; Stellato, Daniel; Ghate, Sameer R.; Ndife, Briana; Moynahan, Aaron; Mishra, Dinesh; Gunda, Praveen; Koruth, Roy; Delea, Thomas E. Journal: Journal of medical economics Issue: Volume 22:Number 12(2020) Page Start: 1243 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe. (31st December 2022) Authors: Mancuso, Maria Elisa; Castaman, Giancarlo; Pochopien, Michal; Aballéa, Samuel; Drzewiecka, Aleksandra; Hakimi, Zalmai; Nazir, Jameel; Fatoye, Francis Journal: Journal of medical economics Issue: Volume 25:Number 1(2022) Page Start: 1068 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment. (2nd January 2020) Authors: Droege, Marcus; Sproule, Douglas; Arjunji, Ramesh; Gauthier-Loiselle, Marjolaine; Cloutier, Martin; Dabbous, Omar Journal: Journal of medical economics Issue: Volume 23:Number 1(2020) Page Start: 70 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Real-world comparison of hospitalization costs for heart failure in type 2 diabetes mellitus patients with established cardiovascular disease treated with canagliflozin versus other antihyperglycemic agents. (2nd April 2020) Authors: Chen, Yen-Wen; Voelker, Jennifer; Tunceli, Ozgur; Pericone, Christopher D.; Bookhart, Brahim; Durkin, Michael Journal: Journal of medical economics Issue: Volume 23:Number 4(2020) Page Start: 401 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States. (1st February 2019) Authors: Pilon, Dominic; Teeple, Amanda; Zhdanava, Masha; Ladouceur, Martin; Ching Cheung, Hoi; Muser, Erik; Lefebvre, Patrick Journal: Journal of medical economics Issue: Volume 22:Number 2(2019) Page Start: 196 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Value of clinical trial narrative data to estimate the costs of adverse event management: a feasibility study. (3rd March 2020) Authors: Mladsi, Deirdre; Hess, Lisa M.; Barnett, Christine L.; Njue, Annete; Huang, Yu-Jing; Cui, Zhanglin Lin; Bowman, Lee Journal: Journal of medical economics Issue: Volume 23:Number 3(2020) Page Start: 213 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗